Free tool
FAERS Monitor: Aklief
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211527 or its brand name (Aklief, Trifarotene). Reports on generic versions are filed under their own applications.
Reports
183
Serious
43
23% of reports
Hospitalization
9
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- erythema28
- acne17
- skin burning sensation17
- urinary retention16
- dry skin15
- mydriasis15
- skin exfoliation14
- skin irritation13
- off label use12
- drug ineffective11
- vision blurred10
- pain of skin9
- product use in unapproved indication9
- skin hyperpigmentation9
- intentional underdose7
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 1 |
| 2020 | 26 |
| 2021 | 41 |
| 2022 | 20 |
| 2023 | 42 |
| 2024 | 21 |
| 2025 | 18 |
| 2026 | 14 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,976 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| mydriasisSignal | 15 | 134.5 | 82.8 | 1,856 |
| skin hyperpigmentationSignal | 9 | 120.5 | 63.7 | 950 |
| intentional underdoseSignal | 7 | 110.2 | 53.3 | 652 |
| urinary retentionSignal | 16 | 55.1 | 34.5 | 798 |
| pain of skinSignal | 9 | 38.4 | 20.3 | 292 |
| skin irritationSignal | 13 | 32.6 | 19.3 | 368 |
| skin burning sensationSignal | 17 | 27.3 | 17.3 | 406 |
| acneSignal | 17 | 25.8 | 16.4 | 382 |
| skin exfoliationSignal | 14 | 19.1 | 11.5 | 223 |
| erythemaSignal | 28 | 15.7 | 11.1 | 373 |
| dry skinSignal | 15 | 12.9 | 8.0 | 154 |
| vision blurredSignal | 10 | 8.4 | 4.6 | 58 |
| product use in unapproved indicationSignal | 9 | 4.2 | 2.2 | 19 |
| off label use | 12 | 1.6 | 0.9 | 2 |
| drug ineffective | 11 | 1.0 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.